Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345017 | 0.86 | SORD (0.51) | SORDOGASLC6A7KDM4EHPGD | |
| SCHEMBL15341857 | 0.82 | SORD (0.41) | SORDOGA | |
| SCHEMBL7900349 | 0.80 | SORD (0.49) | SORDSLC6A7KDM4EHPGDALDH1A1 | |
| SCHEMBL7474572 | 0.80 | SORD (0.49) | SORDSLC6A7KDM4EHPGDALDH1A1 | |
| SCHEMBL7899054 | 0.80 | SORD (0.49) | SORDSLC6A7KDM4EHPGDALDH1A1 | |
| SCHEMBL13033008 | 0.78 | KMT2A (0.56) | SORDOGASLC6A7KDM4EHPGD | |
| SCHEMBL27810118 | 0.78 | KDM4E (0.53) | SORDKDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL29371074 | 0.76 | KDM4E (0.54) | SORDSLC6A7KDM4EHPGDALDH1A1 | |
| SCHEMBL9488628 | 0.76 | SORD (0.56) | SORDOGASLC6A7 | |
| SCHEMBL7904079 | 0.76 | SORD (0.55) | SORDOGASLC6A7KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | SORD 265/4885OGA 1700/4885SLC6A7 2185/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | SORD 265/4885OGA 1700/4885SLC6A7 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.